Patient P-03003
Therapy response
Improving
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
54%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S08
- Day 56 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 61 GI-04 recommended — GI Support Protocol GI-04
- Day 62 Patient accepted — Started GI-04 in the companion
- Day 65 SC-12 recommended — Supportive Compound SC-12
- Day 66 Patient accepted — Started SC-12 in the companion
- Day 70 No meaningful change — GI Support Protocol GI-04
- Day 72 GI symptom burden −10% vs expected — Supportive Compound SC-12
- Day 78 Tolerance state changed — Unstable → Improving
- Day 80 ME-01 recommended — Monitoring Escalation ME-01
- Day 81 Patient accepted — Started ME-01 in the companion
- Day 84 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 56.
Primary contributors, last 14 days
- GI instability-19
- Treatment adherence-11
- Inflammatory activity-10
- Nutritional resilience+8
- Toxicity+2
What helped?
- GI Support Protocol GI-04Day 61Result: no meaningful change
- Supportive Compound SC-12Day 65Result: symptom burden −10%
- Monitoring Escalation ME-01Day 80Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
47%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 63% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 46
- WearableHRV 22 ms, trending down
- Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 79 bpm
- Wearable2,475 steps/day
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Drug metabolism and exposure ↑20
- BloodToxicity index 42
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.9 · butyrate capacity 46/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 21 ms
- Sleep
- 6.9 h
- Steps
- 2,244
- Resting HR
- 77 bpm
Daily log: GI score 45, nutritional resilience 47, adherence 40.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03049 | 42% | S14 | GI-04 | improved | 49 |
| P-03081 | 40% | S10 | GI-04 | improved | 53 |
| P-03123 | 39% | S14 | GI-04 | improved | 50 |
| P-03226 | 39% | S05 | GI-04 | improved | 43 |
| P-03251 | 38% | S14 | SC-12 | improved | 54 |
| P-03037 | 37% | S14 | NP-02 | improved | 43 |
| P-03430 | 37% | S14 | SC-12 | improved | 45 |
| P-03323 | 36% | S14 | GI-04 | improved | 48 |
| P-03090 | 35% | S02 | GI-04 | improved | 48 |
| P-03159 | 35% | S14 | GI-04 | improved | 37 |
| P-03341 | 35% | S14 | NP-02 | improved | 49 |
| P-03384 | 34% | S01 | — | — | 55 |